PURPOSE: In patients with diffuse large B-cell lymphoma (DLBCL), most relapses occur within the first 2 years of diagnosis. We sought to define the rate and outcome of late relapses that occurred after achieving event-free survival at 24 months (EFS24). METHODS: We prospectively followed 1,324 patients with newly diagnosed DLBCL from 2002 to 2015 and treated with immunochemotherapy. Cumulative incidences of late DLBCL and indolent lymphoma relapses were analyzed as competing events. Postrelapse survival was defined as time from first relapse to death from any cause. RESULTS: In 847 patients who achieved EFS24, the cumulative incidence of late relapse was 6.9% at 3 years, 9.3% at 5 years, and 10.3% at 8 years after EFS24. The incidence of DLBCL relapse was similar in patients with DLBCL alone at diagnosis (6.3% at 5 years), compared with patients with concurrent indolent lymphoma at diagnosis (5.2%; P = .46). However, the rate of indolent lymphoma relapse was higher in patients with concurrent indolent lymphoma (7.4% v 2.1% at 5 years; P < .01). In patients with DLBCL alone, the rate of DLBCL relapse was similar in the germinal center B-cell-like (GCB) (4.1% at 5 years) and non-GCB (4.0%; P = .71) subtypes, whereas the rate of indolent lymphoma relapse was higher in patients with the GCB subtype (3.9% v 0.0% at 5 years; P = .02). Postrelapse survival was inferior for patients who relapsed with DLBCL than for those who relapsed with indolent lymphoma (median 29.9 months v unreached; P < .01). CONCLUSION: Patients with DLBCL with a concurrent indolent lymphoma and those with the GCB subtype had a higher rate of late relapse, owing to increased relapses with indolent lymphoma. Patients who relapsed with DLBCL had a worse prognosis than those who relapsed with indolent lymphoma.
PURPOSE: In patients with diffuse large B-cell lymphoma (DLBCL), most relapses occur within the first 2 years of diagnosis. We sought to define the rate and outcome of late relapses that occurred after achieving event-free survival at 24 months (EFS24). METHODS: We prospectively followed 1,324 patients with newly diagnosed DLBCL from 2002 to 2015 and treated with immunochemotherapy. Cumulative incidences of late DLBCL and indolent lymphoma relapses were analyzed as competing events. Postrelapse survival was defined as time from first relapse to death from any cause. RESULTS: In 847 patients who achieved EFS24, the cumulative incidence of late relapse was 6.9% at 3 years, 9.3% at 5 years, and 10.3% at 8 years after EFS24. The incidence of DLBCL relapse was similar in patients with DLBCL alone at diagnosis (6.3% at 5 years), compared with patients with concurrent indolent lymphoma at diagnosis (5.2%; P = .46). However, the rate of indolent lymphoma relapse was higher in patients with concurrent indolent lymphoma (7.4% v 2.1% at 5 years; P < .01). In patients with DLBCL alone, the rate of DLBCL relapse was similar in the germinal center B-cell-like (GCB) (4.1% at 5 years) and non-GCB (4.0%; P = .71) subtypes, whereas the rate of indolent lymphoma relapse was higher in patients with the GCB subtype (3.9% v 0.0% at 5 years; P = .02). Postrelapse survival was inferior for patients who relapsed with DLBCL than for those who relapsed with indolent lymphoma (median 29.9 months v unreached; P < .01). CONCLUSION: Patients with DLBCL with a concurrent indolent lymphoma and those with the GCB subtype had a higher rate of late relapse, owing to increased relapses with indolent lymphoma. Patients who relapsed with DLBCL had a worse prognosis than those who relapsed with indolent lymphoma.
Authors: Thomas M Habermann; Edie A Weller; Vicki A Morrison; Randy D Gascoyne; Peter A Cassileth; Jeffrey B Cohn; Shaker R Dakhil; Bruce Woda; Richard I Fisher; Bruce A Peterson; Sandra J Horning Journal: J Clin Oncol Date: 2006-06-05 Impact factor: 44.544
Authors: Bertrand Coiffier; Eric Lepage; Josette Briere; Raoul Herbrecht; Hervé Tilly; Reda Bouabdallah; Pierre Morel; Eric Van Den Neste; Gilles Salles; Philippe Gaulard; Felix Reyes; Pierre Lederlin; Christian Gisselbrecht Journal: N Engl J Med Date: 2002-01-24 Impact factor: 91.245
Authors: Carrie A Thompson; Herve Ghesquieres; Matthew J Maurer; James R Cerhan; Pierre Biron; Stephen M Ansell; Catherine Chassagne-Clément; David J Inwards; Thérèse Gargi; Patrick B Johnston; Emmanuelle Nicolas-Virelizier; William R Macon; Marie Peix; Ivana N Micallef; Catherine Sebban; Grzegorz S Nowakowski; Luis F Porrata; George J Weiner; Thomas E Witzig; Thomas M Habermann; Brian K Link Journal: J Clin Oncol Date: 2014-09-29 Impact factor: 44.544
Authors: Christian Gisselbrecht; Bertram Glass; Nicolas Mounier; Devinder Singh Gill; David C Linch; Marek Trneny; Andre Bosly; Nicolas Ketterer; Ofer Shpilberg; Hans Hagberg; David Ma; Josette Brière; Craig H Moskowitz; Norbert Schmitz Journal: J Clin Oncol Date: 2010-07-26 Impact factor: 44.544
Authors: L Sanz; A López-Guillermo; C Martínez; F Bosch; J Esteve; F Cobo; S Montoto; M Perales; J Bladé; F Cervantes; B Nomdedeu; E Campo; E Montserrat Journal: Eur J Haematol Date: 1998-07 Impact factor: 2.997
Authors: Mehdi Hamadani; Parameswaran N Hari; Ying Zhang; Jeanette Carreras; Görgün Akpek; Mahmoud D Aljurf; Ernesto Ayala; Veronika Bachanova; Andy I Chen; Yi-Bin Chen; Luciano J Costa; Timothy S Fenske; César O Freytes; Siddhartha Ganguly; Mark S Hertzberg; Leona A Holmberg; David J Inwards; Rammurti T Kamble; Edward J Kanfer; Hillard M Lazarus; David I Marks; Taiga Nishihori; Richard Olsson; Nishitha M Reddy; David A Rizzieri; Bipin N Savani; Melhem Solh; Julie M Vose; Baldeep Wirk; David G Maloney; Sonali M Smith; Silvia Montoto; Wael Saber; Onder Alpdogan; Amanda Cashen; Christopher Dandoy; Robert Finke; Robert Gale; John Gibson; Jack W Hsu; Nalini Janakiraman; Mary J Laughlin; Michael Lill; Mitchell S Cairo; Reinhold Munker; Phil A Rowlings; Harry C Schouten; Thomas C Shea; Patrick J Stiff; Edmund K Waller Journal: Biol Blood Marrow Transplant Date: 2014-07-05 Impact factor: 5.742
Authors: Deborah M Stephens; Hongli Li; Michael L LeBlanc; Soham D Puvvada; Daniel Persky; Jonathan W Friedberg; Sonali M Smith Journal: J Clin Oncol Date: 2016-07-05 Impact factor: 44.544
Authors: Roland Schmitz; George W Wright; Da Wei Huang; Calvin A Johnson; James D Phelan; James Q Wang; Sandrine Roulland; Monica Kasbekar; Ryan M Young; Arthur L Shaffer; Daniel J Hodson; Wenming Xiao; Xin Yu; Yandan Yang; Hong Zhao; Weihong Xu; Xuelu Liu; Bin Zhou; Wei Du; Wing C Chan; Elaine S Jaffe; Randy D Gascoyne; Joseph M Connors; Elias Campo; Armando Lopez-Guillermo; Andreas Rosenwald; German Ott; Jan Delabie; Lisa M Rimsza; Kevin Tay Kuang Wei; Andrew D Zelenetz; John P Leonard; Nancy L Bartlett; Bao Tran; Jyoti Shetty; Yongmei Zhao; Dan R Soppet; Stefania Pittaluga; Wyndham H Wilson; Louis M Staudt Journal: N Engl J Med Date: 2018-04-12 Impact factor: 91.245
Authors: Matthew J Maurer; Lasse H Jakobsen; Raphael Mwangi; Norbert Schmitz; Umar Farooq; Cristopher R Flowers; Peter de Nully Brown; Carrie A Thompson; Henrik Frederiksen; David Cunningham; Judit Jørgensen; Viola Poeschel; Grzegorz Nowakowski; John F Seymour; Francesco Merli; Corinne Haioun; Hervé Ghesquieres; Marita Ziepert; Hervé Tilly; Gilles Salles; Qian Shi; Tarec C El-Galaly; Thomas M Habermann Journal: Am J Hematol Date: 2021-03-18 Impact factor: 10.047
Authors: Madeleine R Berendsen; Wendy B C Stevens; Michiel van den Brand; J Han van Krieken; Blanca Scheijen Journal: Cancers (Basel) Date: 2020-11-28 Impact factor: 6.639
Authors: Grzegorz S Nowakowski; Annalisa Chiappella; Randy D Gascoyne; David W Scott; Qingyuan Zhang; Wojciech Jurczak; Muhit Özcan; Xiaonan Hong; Jun Zhu; Jie Jin; David Belada; Juan Miguel Bergua; Francesco Piazza; Heidi Mócikova; Anna Lia Molinari; Dok Hyun Yoon; Federica Cavallo; Monica Tani; Kazuhito Yamamoto; Koji Izutsu; Koji Kato; Myron Czuczman; Sarah Hersey; Adrian Kilcoyne; Jacqueline Russo; Krista Hudak; Jingshan Zhang; Steve Wade; Thomas E Witzig; Umberto Vitolo Journal: J Clin Oncol Date: 2021-02-23 Impact factor: 44.544